Perifosine downregulates \textit{MDR1} gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line

X. LIN\textsuperscript{1,*}, X. ZHANG\textsuperscript{2,‡}, Q. WANG\textsuperscript{1,*}, J. LI\textsuperscript{1}, P. ZHANG\textsuperscript{3}, M. ZHAO\textsuperscript{1}, X. LI\textsuperscript{4}

\textsuperscript{1}Department of Pathology, Provincial Hospital affiliated to Shandong University, Jinan 250021, China; \textsuperscript{2}Department of Pathology, Medical School of Shandong University, Jinan 250012, China; \textsuperscript{3}Institution of Biochemistry and Molecular Biology, Medical School of Shandong University, Jinan 250012, China; \textsuperscript{4}Surgery of Breast and Thyroid, Provincial Hospital affiliated to Shandong University, Jinan 250012, China

*Correspondence: wangxiu163.com
‡Contributed equally to this work.
Received September 3, 2011 / Accepted November 4, 2011

P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) is the major clinical impediment to chemotherapy of breast cancers. Down-regulation of PI3K/Akt pathway has been described as related to reversal of MDR in cancer cells. Here, we investigated the reversal effect on MDR phenotype of perifosine, a new Akt inhibitor, in breast cancer cell lines. In this study, MCF-7/ADM cells and MCF-7 cells were treated with different concentrations of perifosine. Our results suggested that perifosine reversed MDR partially by downregulation of P-gp expression and inhibition of PI3K/Akt/NF-κB pathway in the MCF-7/ADM cell line. The novel Akt inhibitor perifosine may be a promising new drug due to its ability to reverse MDR in human breast cancer cells.

Key words: perifosine, PI3K/Akt, breast cancer, multidrug resistant gene 1, P-glycoprotein

Multidrug resistance (MDR) is a major reason for failure of chemotherapy-based treatment of breast cancer, in which cells become refractory to many structurally and functionally unrelated chemotherapeutic drugs\cite{1}. In clinical situation, MDR is often associated with overexpression of the \textit{MDR1} gene product, P-glycoprotein (P-gp), which is the most important multidrug resistant transporter by reducing the concentration of the intracellular anticancer drugs\cite{2}. Inhibition of P-gp expression or function has become an important approach aimed to reverse P-gp-mediated MDR and improve the efficacy of chemotherapy. However, the use of many reversal compounds has been limited because of pharmacokinetic interactions with anticancer drugs and serious side-effects.

Recently, much attention has been focused on the involvement of the PI3K/Akt cell signal transduction pathway in MDR\cite{3; 4; 5}. The PI3K/Akt signaling pathway is one of the most important signaling pathways in the control of multiple biological processes in cells through activation of the serine/threonine protein kinase Akt, which is the key downstream factor. Once overactivated, Akt can phosphorylates multiple substrates and downstream effectors such as members of the Forkhead family, caspase family, cell cycle protein family and nuclear factor-κB (NF-κB), which contribute collectively to promote cell proliferation, malignancy, invasion and metastasis\cite{6; 7}. Numerous research studies have shown that the hyperactivation of Akt occurred in major human cancers including breast cancer\cite{8; 9}. Some findings have also demonstrated that the activity of Akt in tumor cells increased after exposure to anticancer chemotherapy drugs through activation of the Ras pathway that leads to resistance to other anticancer drugs\cite{10}. Although P-gp is found in a parallel relationship with Akt activity, the mechanism of regulation of \textit{MDR1} by Akt is unclear.

Many small molecular inhibitors of the PI3K/Akt signaling pathway can increase the chemosensitivity of cancer cells to anticancer drugs\cite{11; 12}. These inhibitors have been reported to include Akt-I-1, Akt-I-2 and perifosine\cite{13; 14; 15}. Garcia et al.\cite{15} reported that the PI3K/Akt pathway is involved in MDR in lymphoma cell lines and PI3K/Akt inhibition in which LY294002 correlates down-regulation of NF-κB activity and inhibition of P-gp function. In addition, Barancik et al \cite{11} reported the possible involvement of the PI3K/Akt pathway
in modulation of MDR mediated by P-gp in the L1210/VCR cell line. These results suggest that blockage of the PI3K/Akt pathway might partially reverse P-gp-mediated MDR.

Perifosine is a potentially more novel Akt inhibitor that targets the lipid-binding pleckstrin homology (PH) domain of Akt by prevention of cell membrane recruitment. It has been reported that perifosine may influence the resistance to anticancer-drugs through regulation of the expression of P-gp in leukemia MDR cells [16]. However, the activity of perifosine has not been tested in human tumor cells that overexpress P-gp. In this study, to find a promising drug to overcome MDR, we investigated whether inhibition of Akt via perifosine could reverse the MDR phenotype partially in P-gp-mediated multidrug-resistant human breast cancer MCF-7/ADM cells and primarily look at the probable mechanism involved.

Materials and Methods

Cell lines and cell culture. The parental drug-sensitive human MCF-7 breast cancer cell line and the multidrug-resistant MCF-7/ADM subline were obtained from the National Cancer Institute in the USA. The two cell lines were grown in RPMI 1640 medium (Hyclone), supplemented with 10% heat-inactivated fetal bovine serum (FBS), in an atmosphere of 5% CO₂ at 37 °C.

Cell viability and Cell chemosensitivity assay by MTT in vitro. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were performed to assess the chemosensitivity of cells to perifosine (Frankfurt, Germany), adriamycin and vinblastine. Briefly, Cells were seeded in 96-well plates at a density of 5x10⁴ cells/well and cultured overnight; perifosine at a range of concentrations (5, 10 or 15 μM) in medium that contained adriamycin (or vinblastine) was then added to the cells for another 24 h. A stock solution of perifosine (40mM) was prepared in dimethylsulfoxide (DMSO); cells cultured in the presence of DMSO alone and of perifosine (40mM) was prepared in dimethylsulfoxide (DMSO); cells cultured in the presence DMSO alone and with the same perifosine concentrations served as the negative control. At the end of the incubation, 20 μl MTT solution (4 mg/ml) and 10 μl of 0.1 M sodium succinate were added to each well and the cells were incubated for a further 4 h at 37 °C in the dark. The intracellular MTT stain was solubilized with 50 μl of dimethyl sulfoxide (DMSO) (Sigma) and mixed thoroughly for 15 min. Spectrometric absorption at a wavelength of 570 nm was measured on a microplate reader (Bio-Ted, USA). The survival rates of the cells were calculated as follows: cell viability= [A570(anticancer drug+)]/A 570(anticancer drug-)x100%. Growth inhibition (%) = 100 – cell survival rate (%). A dose-response curve was plotted and IC₅₀ values were calculated from at least three independent experiments. The multidrug resistance reversal effect was evaluated as a decrease in IC₅₀ for adriamycin or vincristine induced by the presence of perifosine. Fold changes in reversal were calculated by comparison of IC₅₀ for anticancer drugs (adriamycin) to IC₅₀ for anticancer drugs plus perifosine in MCF-7/ADM cells. All analyses were performed in three separate experiments.

Detection of mdr1 mRNA expression by reverse transcription polymerase chain reaction (RT-PCR). Total RNA was obtained from cells by using an RNA Isolation Kit (TaKaRa). The RNA samples were reverse transcribed using a reverse transcriptase kit (TaKaRa) with random primers in a 20-μl final volume and in accordance with the manufacturer's protocols. Quantitative real-time PCR (qPCR) was used to detect P-gp mRNA. qPCR was performed using SYBR Green Real-time PCR MasterMix (TOYOBO). The sequences of the primers used for amplification of mRNA are as follows, MDR1: sense: 5’-CCC ATC ATT GCA ATA GCA GG-3’, antisense: 5’-GTT CAA ACT TCT GCT CCT GA-3’; and β-actin: sense: 5’-ACC CCC ACT GAA AAA GAT GA-3’, antisense: 5’-ATC TTC AAA CCT CCA TGA TG-3’. The final reaction volume was 25 μl, and an iCycler iQ Real-time PCR Detection System (Bio-Rad) was used for qPCR. The amplification data were calculated using the ΔΔCq method which was used to calculate relative mRNA expression. The relative target gene expression was calculated using the formula for 2-ΔΔCq, where ΔΔCq = target Cq – control Cq. ΔCq =Cq target -Cq control. The PCR products (10 μl) were electrophoresed on 2% agarose gel containing ethidium bromide and visualized by UV illumination to identify the specificity.

Quantifying the P-gp, Akt, p-Akt(Ser473) and NF-κB p65 expression by Western blotting. Western blotting was performed as described previously[17]. Cells (2x10⁴) were seeded in 25cm² flasks and were incubated for 24 h at 37 °C before treatment. For extraction of total cell proteins, cells were lysed in homogenization buffer that consisted of 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.2 % sodium azide, 0.1 % sodium dodecyl sulfate (SDS), 0.1 % NP-40 and 0.5 % sodium deoxycholate. For nuclear protein extraction, the Nuclear Protein Extraction Kit (KeyGEN, Nanjing, China) was used in accordance with the manufacturer's instructions. Cell lysates (20 μg) were separated by SDS-PAGE and blotted onto nitrocellulose membranes (Bio-Rad). To avoid non-specific binding, the filters were incubated in 5% skimmed milk in TBST[10 mM Tris (pH 7.4), 150 mM NaCl, 0.1% Tween 20] for 2 h at room temperature. Membranes were then incubated overnight at 4 °C in 5% non-fat milk in TBST that contained antibodies to either P-gp (Santa Cruz, CA, USA), p-Akt (Ser473), Akt, NF-κB p65 or β-actin (Beverly, MA, USA). The antibodies against Akt, phospho-Akt (Ser473), P-gp, NF-κB p65 and β-actin were diluted 1:5000, 1:4000, 1:2000 and 1:4000 respectively. Incubation with antibody was followed by a 30 min incubation with the peroxidase-conjugated secondary antibody. The protein blots were visualized using an enhanced chemiluminescence detection system (ECL Kit Amersham). The intensity of each band was quantified using NIH Image J software.

Rhodamine 123 by flow cytometry to detect the function of P-gp. To detect the P-gp function as a transporter, Rhodamine 123 (Rhod 123, Sigma, St. Louis, MO, USA) was used as a fluorescence tracer. The cells were preincubated in the absence or presence of adriamycin (15 μM), vincristine (280 ng/ml),
or perifosine (5, 10 and 15 μM) for 30 min, 30 min and 24 h in an incubator at 37 °C and 5% CO₂ in air. Subsequently, cells were incubated in RPMI 1640 medium that contained 5 μg/ml Rh 123 at 37 °C in a humidified atmosphere of 5% CO₂ in air for 30 min. The cells were then washed twice with PBS, and re-suspended in fresh Rh 123-free culture medium at 30 min. Green fluorescence, which indicated cellular Rh 123 accumulation, was analyzed using a flow cytometer (Becton Dickinson, San Jose, CA, USA). All analyses were performed in triplicate in three separate experiments and the results were expressed as the mean fluorescence intensity.

Statistical analysis. Data analysis was processed by SPSS 11.0 software. All data were plotted as means ± standard deviation. Student’s t-test was used for comparisons. Differences were considered significant at P-value < 0.05. Each mean was calculated at least three independent times.

Results

Perifosine ameliorated high activation of Akt in the resistant MCF-7/ADM cells. The MDR cell line MCF-7/ADM overexpressing P-gp is derived from the MCF-7 cell line, which is resistant with wide drug resistance and impaired intracellular drug accumulation. The resistant MCF-7/ADM cells were observed to have a higher expression of p-Akt than that of sensitive cells by western blot. Akt phosphorylation at Ser 473 showed an increase in expression of p-Akt of 52.2% in MCF-7/ADM cells when compared with MCF-7. However, the total amount of Akt protein was unchanged, which demonstrated a true increase in the phosphorylation status of Akt in the resistant P-gp-mediated MDR breast cell line (Fig. 1). In addition, phosphorylation levels of Akt were reduced significantly in perifosine treated MCF-7/ADM cells in a dose-dependent manner.

![Figure 1](image-url)

**Figure 1.** Perifosine ameliorates high activation of Akt in the resistant MCF-7/ADM cells

A. Expression of p-Akt (Ser473) and total Akt levels were evaluated by western blotting in MCF-7/ADM cells and MCF-7 cells. The antibody to β-actin demonstrated equal loading in the lanes. The density of each band was quantified using Image software and the ratio of bands was calculated and represented as relative expression level. P-Akt (Ser473) level was much higher in MCF-7/ADM cells than that in MCF-7 cells. MCF-7/ADM cells expressed total Akt at levels similar to those of MCF-7 cells. Each value represents the mean ± standard deviation (S.D.) of three independent experiments; **P < 0.05.

B. MCF-7/ADM cells were treated for 24 h with the indicated concentration of perifosine and the p-Akt levels were determined by western blotting. The p-Akt (Ser 473) expression was reduced significantly in perifosine treated cells compared with DMSO treated control cells and in a dose-dependent manner. The expression level of total Akt in MCF-7/ADM cells did not differ after treatment with perifosine as the blot in the middle of the figure shows. The blot in lower part of the figure shows the levels of β-actin used to monitor equal loading of cytosolic proteins; **P < 0.05.
PERIFOSINE DOWNREGULATES MDR1-MEDIATED MULTIDRUG-RESISTANCE

manner. Dephosphorylation of Akt at Ser 473 reduced expression of p-Akt by 65.1% after 24 h of incubation with 15 μM perifosine. However, perifosine treatment reduced only the phosphorylation level of Akt but without modifying the total amount of Akt protein (Fig. 1).

Perifosine inhibited cell viability significantly. MTT assays showed that perifosine induced a significant decrease in cell viability in a dose- and time-dependent manner. At 24 h, the IC_{50} for perifosine was 4.3 ± 0.1 μM for MCF-7 cells, while it was 14.1 ± 1.3 μM for MCF-7/ADM cells. Therefore, we chose perifosine at a concentration of 5 μM for MCF-7 cells and 15 μM for MCF-7/ADM cells to perform the subsequent experiments. Cell viability decreased with increasing perifosine concentrations. Treatment with 15 μM perifosine for 2 days resulted in a 20.0% cell survival rate. A plot of cell growth graph showed that perifosine inhibited cell viability significantly by 51.0%, 66.7%, and 79.3% at 24 h, 48 h, and 72 h respectively for the MCF-7/ADM cells with 15 μM perifosine (Fig. 2).

Perifosine increased the chemosensitivity of MCF-7/ADM cells to adriamycin and vinblastine. The exposure of MCF-7/ADM cells to perifosine resulted in a significant reduction of resistance of these cells against adriamycin and vinblastine in a concentration-dependent manner. IC_{50} in MCF-7/ADM cells to adriamycin was 14.5μM. However, after treatment with perifosine (5, 10 and 15 μM), the IC_{50} levels of the cells for adriamycin were reduced to 4.58, 2.97, 1.02 μM, respectively, which was equivalent to a 3, 5 or 14-fold reduction of resistance for adriamycin (P=0.028). Furthermore, the drug resistance to vinblastine was reduced significantly from 288 to 18.45, 9.48, or 6.91ng/l, respectively, which was equivalent to a 17-, 30-, or 43-fold reduction of resistance for vinblastine in perifosine treated cells and DMSO treated cells, respectively (P=0.013) (Table 1).

Table 1. Effect of perifosine on chemosensitivity to cytotoxic drugs in MCF-7/ADM cells

<table>
<thead>
<tr>
<th>Cell</th>
<th>IC50(μM) for adriamycin</th>
<th>Relative drug resistance (fold reversal)</th>
<th>IC50(ng/ml) for vinblastine</th>
<th>Relative drug resistance (fold reversal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-7</td>
<td>0.11±0.05</td>
<td>1</td>
<td>0.97±0.15</td>
<td>1</td>
</tr>
<tr>
<td>MCF-7/ADM</td>
<td>14.5±1.01</td>
<td>131.8</td>
<td>279±8.60</td>
<td>288</td>
</tr>
<tr>
<td>MCF-7/ADM+DMSO</td>
<td>13.9±2.56</td>
<td>126.3</td>
<td>251±4.44</td>
<td>259</td>
</tr>
<tr>
<td>MCF-7/ADM+Perifosine(5μM)</td>
<td>4.58±0.45</td>
<td>41.64 (3-fold)</td>
<td>17.9±1.63</td>
<td>18.45 (17-fold)</td>
</tr>
<tr>
<td>MCF-7/ADM+Perifosine(10μM)</td>
<td>2.97±0.24</td>
<td>27.00 (5-fold)</td>
<td>9.2±2.01</td>
<td>9.48 (30-fold)</td>
</tr>
<tr>
<td>MCF-7/ADM+Perifosine(15μM)</td>
<td>1.02±0.33</td>
<td>9.27 (14-fold)</td>
<td>6.7±1.10</td>
<td>6.91 (43-fold)</td>
</tr>
<tr>
<td>MCF-7/ADM+LY294002(10μM)</td>
<td>5.62±0.19</td>
<td>51.10 (3-fold)</td>
<td>20.1±0.34</td>
<td>13.88 (21-fold)</td>
</tr>
</tbody>
</table>

The value of relative drug resistance was the IC_{50} of the treated cells to MCF-7 cells. The fold reversal was calculated by comparing the IC_{50} of perifosine treated cells for anticaner drugs (adriamycin or vinblastine) to IC_{50} of MCF-7 cells for adriamycin. The drug resistance was markedly reduced in the cells treated with perifosine in comparison with MCF-7/ADM cells. In the cells treated with perifosine (15μM), a 14-fold reduction of resistance for adriamycin and 43-fold reduction of resistance for vinblastine respectively were shown.
Perifosine efficiently inhibited the expression and function of P-gp. The expression of *MDR1* at both mRNA and protein levels were evaluated by qPCR or western blotting analysis in a dose-dependent manner. MCF-7/ADM cells had high expression levels of *MDR1* mRNA and P-gp, but high expression was not found in the parental MCF-7 cells. After treatment with 15μM perifosine the *MDR1* mRNA level was decreased to 23.1%. Western blotting analysis was performed using an antibody specific for P-gp. The results showed that the P-gp level was decreased strongly by 74.4% following with exposure to perifosine for 36 h. (Fig. 3A. and Fig. 3B.) The Rhd 123 retention in the cells as seen by flow cytometry demonstrated that intracellular Rhd 123 levels were enhanced in MCF-7/ADM cells after treatment with 5 μM perifosine and the inhibition effect of P-gp efflux persisted and increased in a dose-dependent manner. (Fig. 4.)

**Perifosine downregulated levels of nuclear NF-κB p65 expression.** Some studies have shown that the PI3K/Akt signaling pathway may play an important role in expression of the human *MDR1* gene via the transactivation of NF-κB. We determined to detect the change in expression levels of NF-κB p65, the most important member of the NF-κB family, in cells after treatment with perifosine. The results suggested that the presence of perifosine significantly decreased the levels of nulear NF-κB p65 in comparison with control conditions, as shown in Fig.5.

**Discussion**

Multidrug resistance (MDR) is a major factor in the failure of chemotherapy-based treatment of breast cancer [1]. MDR is
PERIFOSINE DOWNREGULATES MDR1-MEDIATED MULTIDRUG-RESISTANCE

characterized by cross-resistance to a broad range of unrelated anti-neoplastic drugs with different molecular structures or different target sites that may lead to recurrence and metastasis of the tumor. The most common mechanism for MDR in cancer cells is overexpression of the P-glycoprotein (P-gp), which is encoded by the $MDR1$ gene which function as an ATP-dependent transporter and has the effect of reducing the concentration of the anticancer drugs intracellularly [2]. Many reports appeared with using verapamil in clinical trials in an attempt to overcome MDR. However, their toxicities and side effects have limited their use. The search for a new approach to restore the sensitivity of the tumor cell and reverse MDR is an urgent priority [18; 19].

Upregulation of the PI3K/Akt pathway was described as possibly relate to MDR in some MDR cancer cell lines, including L1210/VCR, LBR/V160 and LBR/D160. Perifosine is a novel and specific inhibitor of Akt that is considered as a most effective antitumor drug because of its favorable pharmacokinetic and toxicity profiles found in clinical phase I/II trials [20]. It may become one of the more effective anticancer drugs against refractory breast cancer, prostate cancer, pancreatic cancer and lung cancer. Furthermore, it is also in a novel class of antitumor agents that do not cause significant hematological toxicity [21]. Several studies have shown that perifosine may regulate the chemosensitivity of cancer cells such as leukemia cells to antitumor drugs, but to the best of our knowledge, there has been no study on solid human cancer cells [15; 22]. In this study, the findings reveal that perifosine can reverse P-gp-mediated MDR partially in breast cancer cells through suppression of the PI3K/Akt pathway and downregulation of P-gp expression.

High activation of the PI3K/Akt pathway has been observed frequently in breast cancer patients and it is likely that is contributes to drug resistance [23]. P-gp overexpression has also been detected in breast cancer patients and correlates negatively with complete remission achievement [24]. Therefore it is likely that some breast cancer patients would exhibit PI3K/Akt up-regulation together with P-gp overexpression, even if this change has not been shown in a conclusive manner [25]. In the present study, we firstly demonstrated that higher Akt activity presented in resistant MCF-7/ADM cells compared with sensitive MCF-7 cells. Moreover, the higher Akt activity could be decreased by addition of perifosine, but without changing levels of total Akt kinase. Our results are in line with previous reports in other cancer MDR cells, including leukemia cells, gastric cancer cells, which suggested that a high p-Akt level correlates with MDR and that perifosine can reduce the p-Akt levels efficiently [11; 16; 26].

Therefore, we addressed the inhibition of the PI3K/Akt pathway with perifosine induced cell growth inhibition in MCF-7/ADM cells and MCF-7 cells. The cell inhibition rate of MCF-7/ADM cells was much higher than that of MCF-7 cells at its IC$_{50}$ of perifosine, thus indicating that PI3K/Akt activation may be essential for the survival of MDR breast cancer cell lines [16]. The IC$_{50}$ of MCF-7/ADM cells to perifosine was higher than that of MCF-7 cells. This finding could have resulted from the higher level of p-Akt and P-gp in MCF-7/ADM cells than that in MCF-7 cells and that enhanced cell growth and decreased cell apoptosis.

We next examined whether perifosine could increase the chemosensitivity of MCF-7/ADM cells to anticancer drugs such as adiramycin and vinblastine. Perifosine (15 μM) lowered
the IC_{50} of the MCF-7/ADM cells from 14.5 μM to 1.02 μM, equivalent to a 14-fold reduction of resistance for adriamycin. Furthermore, the drug resistance to vinblastine was reduced in perifosine treated cells (43-fold) (P<0.01). These findings suggested that perifosine may reverse partially the MDR phenotype of MCF-7/ADM cells. Inhibition of the PI3K/Akt pathway provides a new molecular target for the therapy of resistant breast cancer that includes co-treatment of anticancer drugs with perifosine.

In this study, perifosine was capable of reducing the expression both MDR1 mRNA and P-gp in a breast cancer cell line with a dose- and time-dependent manner. This finding means that P-gp is one of the key factors downstream of the PI3K/Akt pathway and is the important target to overcome MDR by perifosine. However, some researchers have shown that MRP1, but not P-gp, expression is under the control of the PI3K/Akt axis in acute myelogenous leukemia blasts [30]. The regulation of other MDR-related proteins needs more investigations. In this study, we also demonstrated that following treatment with perifosine, levels of intracellular Rhd 123 were enhanced in MCF-7/ADM cells (5 μM perifosine) and the inhibition effect of P-gp efflux persisted upwards in a dose-dependent manner. These findings indicated that perifosine had an effect on the restoration of the sensitivity to adriamycin by reducing not only P-gp expression but also its function. Our results are consistent with recent reports highlighted these effect in leukemia cells [16]. These results indicate that inhibition of the PI3K/Akt pathway by perifosine may overcome partially P-gp-mediated MDR in breast carcinomas.[31; 32].

At present, the transcriptional regulation of the MDR 1 gene by Akt is poorly understood. Akt activates NF-κB in many cell lines [33]; negative regulation of NF-κB by the PI3K/Akt signaling cascade has also been described [34]. Within the human MDR1 promoter, an NF-κB binding site located at −6029 nt from the transcription start site has been reported to be involved in carcinogen- induced MDR1 gene expression mediated by the PI3K/Akt pathway [35]. NF-κB is a member of the ubiquitously expressed family of Rel-related transcription factors and is sequestered in the cytoplasm by binding to inhibitory κB proteins (IκB) in unstimulated cells. A variety of stimuli, such as oncogenes, allow the translocation of NF-κB to the nucleus, where it binds to the promoter region of target genes involved in the control of different cellular responses, including apoptosis. The mammalian NF-κB family contains five members: p50/p105 (NF-κB1), p52/p100 (NF-κB2), c-Rel, RelB, and p65 (RelA). Detection of nuclear p65 is the representative subunit of NF-κB activity. It has been reported that PI3K/Akt inhibition by Wortmannin and LY294002 can downregulate NF-κB activity through decrease in IκB-α phosphorylation [15]. Here, we examined the expression of nuclear NF-κB p65 protein in MCF-7/ADM cells after treatment with different concentrations of perifosine. The presence of perifosine decreased significantly the levels of nuclear NF-κB p65 protein in comparison with control.
conditions. As perifosine has an effect on AP-1 activity, which also may influence MDR1 expression, NF-κB was at least one of the important nuclear transcriptional factors involved in perifosine-induced suppression of MDR1 expression.

In the present work, we demonstrated that the PI3K/Akt pathway is involved in MDR of breast cancer and that perifosine reversed MDR by downregulation of P-gp through inhibition of the PI3K/Akt/NF-κB pathway in vitro in the MCF-7/ADM cell line. The Akt activity in the PI3K/Akt signaling cascade may be an attractive target for reversal of drug resistance, and perifosine is a promising drug in the effort to overcome drug resistance in breast cancers with high Akt activity.

Acknowledgements: This research was supported by the Scientific Research Foundation for the Excellent Middle-Aged and Youth Scientists of Shandong Province of China (Project No. BS2009YY033).

References


